Soubrane G, Behar-Cohen F
Hôtel-Dieu de Paris, université Paris Descartes, 1, place du Parvis-Notre-Dame, 75004 Paris, France.
Hôpital ophtalmique Jules-Gonin, avenue de France 15, 1000 Lausanne, Suisse.
J Fr Ophtalmol. 2015 Feb;38(2):159-67. doi: 10.1016/j.jfo.2014.09.007. Epub 2015 Jan 16.
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed.
糖尿病性黄斑水肿（DME）是糖尿病视网膜病变的常见并发症，可能导致严重视力丧失。在本文中，我们研究了DME的病理生理学，并综述了各种治疗选择，如激光光凝、抗血管内皮生长因子（VEGF）受体抗体以及包括ILUVIEN（®）在内的类固醇药物，ILUVIEN（®）是一种新型的缓释、不可生物降解、可注射的玻璃体内微植入物，含有醋酸氟轻松。本文还讨论了为评估ILUVIEN（®）治疗DME的疗效和安全性而进行的FAME（糖尿病性黄斑水肿中的醋酸氟轻松）研究结果。
